Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis

Safety of guselkumab with and without prior TNF-α inhibitor treatment: Pooled results across four studies in patients with psoriatic arthritis

(2023) Proton Rahman et al.   JOURNAL OF RHEUMATOLOGY

Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure

(2023) Mark G Lebwohl et al.   BRITISH JOURNAL OF DERMATOLOGY

Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials

(2023) Andrew Blauvelt et al.   BRITISH JOURNAL OF DERMATOLOGY

Biologic therapy for psoriasis is associated with reduced risk of death: Insights from the VA clinical assessment, reporting and tracking program

(2023) Taufiq Salahuddin et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

(2023) Gerd R Burmester et al.   RMD Open

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

(2022) Alice B. Gottlieb et al.   ACTA DERMATO-VENEREOLOGICA

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

(2022) Steven R. Ytterberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Waiting for JAK inhibitor safety data

(2022) Tue Wenzel Kragstrup et al.   RMD Open

Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis

(2022) Kenneth B. Gordon et al.   JAMA Dermatology

Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global Survey

(2022) April Armstrong et al.   Dermatology and Therapy

Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data

(2022) Nancy W. Wei et al.   Journal of Psoriasis and Psoriatic Arthritis

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021

(2022) Laura C. Coates et al.   Nature Reviews Rheumatology

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence

(2022) Angelo Ruggiero et al.   Clinical Cosmetic and Investigational Dermatology

The incidence of opportunistic infections in patients with psoriatic arthritis treated with biologic and targeted synthetic agents: A systematic review and meta-analysis

(2022) Athanasios Vassilopoulos et al.   Frontiers in Pharmacology

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

(2022) Jeffrey R Curtis et al.   ANNALS OF THE RHEUMATIC DISEASES

New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies

(2021) Di Yan et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The safety of JAK-1 inhibitors

(2021) Benjamin Clarke et al.   RHEUMATOLOGY

Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2

(2021) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Real‐world experience with risankizumab in patients with plaque psoriasis: a retrospective study

(2021) M. Mehta et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Real-life efficacy of guselkumab in patients with early psoriatic arthritis

(2021) Ilenia Pantano et al.   RHEUMATOLOGY

Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk

(2021) Lucia Novelli et al.   Frontiers in Medicine

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)

(2021) Laura C Coates et al.   ANNALS OF THE RHEUMATIC DISEASES

Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis

(2021) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

All‐Cause and Cause‐Specific Mortality in Psoriatic Arthritis and Ankylosing Spondylitis: A Systematic Review and Meta‐Analysis

(2021) Haseeb Chaudhary et al.   ARTHRITIS CARE & RESEARCH

Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III , Randomized, Double‐Blind , Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis

(2021) Iain B. McInnes et al.   Arthritis & Rheumatology

Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey

(2021) Mark Lebwohl et al.   Dermatology and Therapy

Blockade of IL-23: What is in the Pipeline?

(2021) Tommaso Lorenzo Parigi et al.   Journal of Crohns & Colitis

Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis

(2020) Sofie Vaengebjerg et al.   JAMA Dermatology

Comorbidities associated with psoriatic arthritis: Review and update

(2020) Lourdes M. Perez-Chada et al.   CLINICAL IMMUNOLOGY

The importance of understanding patient and physician preferences for psoriasis treatment characteristics: a systematic review of discrete-choice experiments

(2020) Noem Sain et al.   CURRENT MEDICAL RESEARCH AND OPINION

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

(2020) Philip J Mease et al.   LANCET

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

(2020) Atul Deodhar et al.   LANCET

Association between uveitis and psoriatic disease: a systematic review and Meta-analysis based on the evidence from cohort studies

(2020) Chao-Ran Li   International Journal of Ophthalmology

Medication persistence on biological therapies prescribed for the treatment of chronic inflammatory arthropathies: a real-world data study

(2020) Marisol Samartín-Ucha et al.   European Journal of Hospital Pharmacy-Science and Practice

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

(2020) Philip Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Reduced Risk of Mortality Associated With Systemic Psoriasis Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A Nested Case-Control Analysis

(2020) Richard G. Langley et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study

(2020) Marco Galluzzo et al.   Journal of Clinical Medicine

Association of Age, Sex, Race, and Geographic Region With Variation of the Ratio of Basal Cell to Cutaneous Squamous Cell Carcinomas in the United States

(2020) Tess M. Lukowiak et al.   JAMA Dermatology

Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review

(2020) Kevin Yang et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection

(2020) Manuela Ceccarelli et al.   Dermatologic Therapy

Skin Cancer Development in Solid Organ Transplant Recipients in Switzerland (Swiss Transplant Cohort Study)

(2020) Nadja Angela Stenz et al.   DERMATOLOGY

Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis

(2019) Yaowei Zhu et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study

(2019) Laura K. Ferris et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis

(2019) Kerasia‐Maria Plachouri et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Patients’ perspectives and experience of psoriasis and psoriatic arthritis: a systematic review and thematic synthesis of qualitative studies

(2019) Daniel Sumpton et al.   ARTHRITIS CARE & RESEARCH

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

(2019) Kristian Reich et al.   LANCET

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

(2019) April Armstrong et al.   Dermatology and Therapy

Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study

(2018) Mamitaro Ohtsuki et al.   JOURNAL OF DERMATOLOGY

Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry

(2018) Bruce Strober et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents

(2018) Shivani B. Kaushik et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

(2018) Atul Deodhar et al.   LANCET

Incidence ratio of basal cell carcinoma to squamous cell carcinoma equalizes with age

(2017) Harvind S. Chahal et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry

(2017) David Fiorentino et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Risk of Uveitis Among People With Psoriasis

(2017) Ching-Chi Chi et al.   JAMA Ophthalmology

Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis

(2016) Silvia Minozzi et al.   Expert Opinion On Drug Safety

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

(2015) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Psoriatic Disease With Uveitis

(2015) Alexander Egeberg et al.   JAMA Dermatology

Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012

(2015) Howard W. Rogers et al.   JAMA Dermatology

Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment

(2015) Christian Kromer et al.   PLoS One

Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort

(2014) O. Ahlehoff et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials

(2013) Richard G. B. Langley et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies

(2013) C. Pouplard et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Cardiovascular Mortality in Psoriasis and Psoriatic Arthritis: Epidemiology, Pathomechanisms, Therapeutic Implications, and Perspectives

(2012) Wolf-Henning Boehncke et al.   Current Rheumatology Reports

Skin cancer in solid organ transplant recipients: Advances in therapy and management

(2011) Fiona O’Reilly Zwald et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.

(2010) K Abuabara et al.   BRITISH JOURNAL OF DERMATOLOGY

The Risk of Stroke in Patients with Psoriasis

(2009) Joel M. Gelfand et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY